Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANeuroTech To Launch Pivotal Program With New Dose Of Old Antidepressant

Pipamperone Promise In MDD

Executive Summary

The Belgian firm has the go-ahead from the US FDA for an advanced depression program for ANT-01 including the endpoint of improvement in cognitive function, which could differentiate its label.

You may also be interested in...



Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.

Seven Potential Blockbuster Approvals To Look Out For In 2023

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.

Sanofi and AZ’s RSV Antibody Gets EU Thumbs Up But Pfizer Rival Hot On Heels

Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel